Cargando…

Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.

The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2 as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and an...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Meerbeeck, J., Debruyne, C., van Zandwijk, N., Postmus, P. E., Pennucci, M. C., van Breukelen, F., Galdermans, D., Groen, H., Pinson, P., van Glabbeke, M., van Marck, E., Giaccone, G.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1996
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074723/ https://www.ncbi.nlm.nih.gov/pubmed/8826866

Ejemplares similares

Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future
por: Reid, Glen, et al.
Publicado: (2020)

Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis
por: Schillebeeckx, Eline, et al.
Publicado: (2021)

Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma
por: Yeo, Dannel, et al.
Publicado: (2021)

External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma
por: Janssens, Eline, et al.
Publicado: (2022)

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
por: van Haarst, J M W, et al.
Publicado: (2002)

MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients
por: Lin, Ruby C.Y., et al.
Publicado: (2016)

Surgical series in mesothelioma: navigating between biases
por: Raskin, Jo, et al.
Publicado: (2023)

Investigational Approaches for Mesothelioma
por: Surmont, Veerle F., et al.
Publicado: (2011)

Cilengitide Inhibits Attachment and Invasion of Malignant Pleural Mesothelioma Cells through Antagonism of Integrins αvβ3 and αvβ5
por: Cheng, Ngan Ching, et al.
Publicado: (2014)

Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways
por: Williams, Marissa, et al.
Publicado: (2019)

Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma
por: Hylebos, Marieke, et al.
Publicado: (2017)

Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales
por: Linton, A, et al.
Publicado: (2014)

Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression
por: Marcq, Elly, et al.
Publicado: (2019)

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma
por: Rovers, Sophie, et al.
Publicado: (2022)

Editorial: Emerging Therapies for Malignant Mesothelioma
por: van Zandwijk, Nico, et al.
Publicado: (2020)

Multimodality treatment of malignant pleural mesothelioma
por: Berzenji, Lawek, et al.
Publicado: (2018)

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
por: Nielsen, Ole S., et al.
Publicado: (2000)

Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study
por: Lamote, Kevin, et al.
Publicado: (2017)

The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
por: Chu, Gerard J., et al.
Publicado: (2019)

Mesothelioma treatment: Are we on target? A review
por: Hiddinga, Birgitta I., et al.
Publicado: (2015)

Headspace Volatile Organic Compound Profiling of Pleural Mesothelioma and Lung Cancer Cell Lines as Translational Bridge for Breath Research
por: Janssens, Eline, et al.
Publicado: (2022)

Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma
por: Williams, Marissa, et al.
Publicado: (2019)

Supplementary Prognostic Variables for Pleural Mesothelioma: A Report from the IASLC Staging Committee
por: Pass, Harvey I., et al.
Publicado: (2014)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM)
por: Wright, Casey M., et al.
Publicado: (2013)

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
por: Kirschner, Michaela B, et al.
Publicado: (2015)

Comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'
por: Kao, S C-H, et al.
Publicado: (2014)

Repetitive responses to nanoparticle albumin‐bound paclitaxel and carboplatin in malignant pleural mesothelioma
por: Kanai, Osamu, et al.
Publicado: (2016)

High dose etoposide for brain metastases of small cell lung cancer. A phase II study. The EORTC Lung Cancer Cooperative Group.
por: Postmus, P. E., et al.
Publicado: (1989)

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.
por: Nielsen, O. S., et al.
Publicado: (1998)

Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?
por: Lagniau, Sabrina, et al.
Publicado: (2017)

An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma
por: Linton, A, et al.
Publicado: (2014)

A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma
por: Kao, Steven C, et al.
Publicado: (2016)

An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma
por: Linton, A, et al.
Publicado: (2018)

Pleural Nodules and Mediastinal Lymphadenopathy in a Smoker: An Unusual Case Report
por: Desbuquoit, Damien, et al.
Publicado: (2016)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma
por: Williams, Marissa, et al.
Publicado: (2015)

Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
por: Kloover, J S, et al.
Publicado: (2004)

Thoracoscopy in Pleural Malignant Mesothelioma Diagnosis
por: Tassi, G. F., et al.
Publicado: (1997)

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.
por: Smit, E. F., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_s14q8ae5vpb604tav3umc7uli6